Company says substantial doubt exists about ability to continue as a going concern over next year
Overview
US biopharmaceutical developer's H1 net loss widened, with loss per share at $1.6
Operating expenses for H1 rose sharply compared to prior year
Company completed merger and domestication, now named Niki BioSolutions
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Loss Per Basic Share
$1.60
Result Drivers
Higher operating expenses - Co said operating expenses rose sharply, driven by increased research and development, general and administrative, and legal costs
Going-concern risks - Co flagged substantial doubt about ability to continue as a going concern due to recurring losses and negative cash flows
NIKI•
